NCT02955758View on ClinicalTrials.gov

Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

April 9, 2024

Study Completion Date

April 9, 2024

Conditions
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
Interventions
BIOLOGICAL

Pembrolizumab

Given IV, 200mg fixed dose, every 3 weeks

Trial Locations (1)

94304

Stanford University, School of Medicine, Palo Alto

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Joel Neal

OTHER

NCT02955758 - Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter